<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728322</url>
  </required_header>
  <id_info>
    <org_study_id>HBB HSC-01</org_study_id>
    <nct_id>NCT03728322</nct_id>
  </id_info>
  <brief_title>iHSCs With the Gene Correction of HBB Intervent Subjests With β-thalassemia Mutations</brief_title>
  <official_title>A Safety and Efficacy Study of a Single Center, Open-label, Single Arm About the Gene Correction of HBB in Patient-specific iHSCs Using CRISPR/Cas9 That Intervent Subjests With β-thalassemia Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allife Medical Science and Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allife Medical Science and Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single centre、single arm、open-label study，to investigate the safety and efficacy of
      the gene correction of HBB in patient-specific iHSCs using CRISPR/Cas9.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of transplantation iHSCs
      intervent subjests with β-thalassemia mutations.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of treatment related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as &gt;= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>iHSCs treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>iHSCs treatment group</intervention_name>
    <description>iHSCs intravenous injection</description>
    <arm_group_label>iHSCs treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects ≥ 2 and ≤ 60 years of age

          2. Subjects was confirmed the transfusion-dependent β-thalassemia

          3. Adequate organ function, as defined by:

             Serum creatinine ≤ 1.5 mg/dl ； Serum ALT/AST）≤2.5×ULN；ALB≥25g/L； Serum total bilirubin
             &lt; 1.5x ULN Left ventricular ejection fraction≥50%

          4. Chest X-ray and ecg test results were normal, no serious cardiopulmonary diseases

          5. Subjects survival was expected≥6 months

          6. Adult patients were willing to use reliable contraceptives (such as condoms) and not
             to donate sperm throughout the study period and within three months of discharge

          7. Subjects and the guardians able to undergo post-physical therapy/rehabilitation

        Exclusion Criteria:

          1. Subjects allergic to macromolecular biological agents such as antibodies or cytokines

          2. Subjects receipt of any investigational clinical trials within 3 months.

          3. Subjects previous treatment with any hematopoietic stem cell transplantation or other
             organ transplantation

          4. Uncontrolled bleeding symptoms

          5. Severe cardiovascular disease is known, including any of the following:

             Myocardial infarction or thrombosis has occurred in the past six months Subjects with
             unstable angina pectoris Subjects with Class III/IV cardiovascular disability
             according to the New York Heart Association Classification

          6. Subjects have one kinds of tumors within 5 years

          7. Active hepatitis B (HBV DNA＞1000copy/mL), hepatitis C or HIV infection.

          8. Subjects have an infectious diseases that cannot be controlled within 4 weeks

          9. subjects have severe central nervous system disease or epilepsy

         10. Subjects are Suffering from mental illness; Patients with alcohol dependence, drug
             abuse, drug addiction, and medical, psychological or social conditions that may
             interfere with research or have an impact on the evaluation of research results

         11. Women in pregnancy (positive urine/blood pregnancy test) or lactation

         12. Subjects who have other conditions that were not appropriate for the group determined
             by the researchers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2018</study_first_posted>
  <last_update_submitted>November 1, 2018</last_update_submitted>
  <last_update_submitted_qc>November 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

